SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 206 filers reported holding SANGAMO THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $402,234 | +3.1% | 128,100 | +36.1% | 0.01% | -16.7% |
Q2 2022 | $390,000 | -28.8% | 94,100 | 0.0% | 0.01% | -14.3% |
Q1 2022 | $548,000 | -56.3% | 94,100 | -43.5% | 0.01% | -50.0% |
Q4 2021 | $1,253,000 | -4.2% | 166,476 | +14.7% | 0.01% | -6.7% |
Q3 2021 | $1,308,000 | -2.9% | 145,100 | +28.7% | 0.02% | -16.7% |
Q2 2021 | $1,347,000 | -56.8% | 112,765 | -54.8% | 0.02% | -73.5% |
Q1 2021 | $3,120,000 | +78.6% | 249,206 | +122.5% | 0.07% | +74.4% |
Q4 2020 | $1,747,000 | +144.0% | 112,000 | +40.0% | 0.04% | +62.5% |
Q2 2020 | $716,000 | +6.9% | 80,000 | -23.8% | 0.02% | -35.1% |
Q1 2020 | $670,000 | +23.4% | 105,000 | +61.5% | 0.04% | +105.6% |
Q4 2019 | $543,000 | +71.3% | 65,000 | +85.7% | 0.02% | +12.5% |
Q3 2019 | $317,000 | -94.7% | 35,000 | -93.7% | 0.02% | -94.7% |
Q2 2019 | $6,002,000 | +1697.0% | 557,200 | +1492.0% | 0.30% | +1583.3% |
Q1 2019 | $334,000 | -61.9% | 35,000 | -43.2% | 0.02% | -73.5% |
Q2 2018 | $876,000 | – | 61,667 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alexandria Capital, LLC | 1,003,725 | $15,663,000 | 1.66% |
Golden State Equity Partners | 123,817 | $1,932,000 | 1.33% |
Rhenman & Partners Asset Management AB | 821,888 | $12,826,000 | 1.05% |
WASATCH ADVISORS LP | 10,072,381 | $157,180,000 | 0.77% |
BOGLE INVESTMENT MANAGEMENT L P /DE/ | 29,636 | $462,000 | 0.73% |
Ceeto Capital Group, LLC | 80,000 | $1,248,000 | 0.63% |
EMC Capital Management | 48,992 | $765,000 | 0.58% |
Fort Sheridan Advisors LLC | 71,173 | $1,111,000 | 0.54% |
Vanguard Capital Wealth Advisors | 34,680 | $584,000 | 0.54% |
Casdin Capital, LLC | 1,080,000 | $16,853,000 | 0.50% |